GT Biopharma

Name

GT Biopharma

Legal name

GT Biopharma, Inc.

Website

https://gtbiopharma.com

Company type

Public

Founded year

1965

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Clinical-stage immuno-oncology biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

akta.pro secondary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Immuno-oncology therapeutics
• NK cell engagers
• Cancer immunotherapy
• Clinical-stage biopharmaceuticals
• Targeted cancer therapies

Headquarters

HQ city

Westlake Village

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-Revenue / Clinical Stage: GT Biopharma is a clinical-stage immuno-oncology company with no approved products and no commercial revenue. The company has never generated product revenues and is entirely dependent on financing activities (equity offerings, registered direct offerings) to fund operations. As of the available data, the company has no revenue-generating streams from product sales, licensing royalties, or services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

GT Biopharma is a clinical-stage immuno-oncology company developing therapeutic agents based on its proprietary TriKE® (Tri-Specific Killer Engager) NK cell engager platform, which generates single-chain recombinant proteins that simultaneously engage natural killer cells and cancer cells to selectively facilitate cancer cell killing. The company has three product candidates in clinical trials: GTB-3650 (CD33+ hematologic malignancies), GTB-5550 (B7-H3+ solid tumors), and GTB-7550 (CD19+ lymphoid malignancies and autoimmune disease).

Product overview

GT Biopharma is a clinical-stage immuno-oncology company developing novel biopharmaceutical drugs based on its proprietary TriKE® (tri-specific Killer Engager) NK cell engager platform. The company's core platform technology generates targeted immunotherapeutic agents that simultaneously engage natural killer cells and cancer cells to selectively facilitate cancer cell killing. The portfolio includes three TriKE candidates in clinical development: GTB-3650 (for CD33+ hematologic malignancies), GTB-5550 (for B7-H3+ solid tumors), and GTB-7550 (for CD19+ lymphoid malignancies and autoimmune disease). The TriKE platform is exclusively licensed from the University of Minnesota.

Differentiator

Problem solved

Functional benefit

Brands

• TriKE®: Proprietary NK cell engager platform technology - tri-specific killer engager platform designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells
• GTB-3650
• GTB-5550
• GTB-7550

Products and services

• TriKE® Platform Proprietary tri-specific natural killer (NK) cell engager platform technology that generates single-chain recombinant proteins with three components: a CD16-engaging nanobody arm, an IL-15 linker arm for NK cell proliferation/priming/survival, and a tumor-targeting nanobody arm. Designed to harness and enhance the cancer-killing abilities of a patient's own NK cells against hematologic malignancies and solid tumors.
• GTB-3650 Second-generation TriKE® candidate using camelid nanobody binding domains, targeting CD33+ hematologic malignancies including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Dosed via two-week blocks (two weeks on, two weeks off) for up to four months. Phase 1 dose escalation trial is ongoing with Cohort 4 enrollment complete and 8 patients treated across the first four cohorts with no dose-limiting toxicities observed.
• GTB-5550 B7-H3-targeted NK cell engager for solid tumors expressing B7-H3. First dual nanobody TriKE® tested with patient-friendly subcutaneous (SQ) injection in the abdominal area for 5 consecutive days during Week 1 and Week 2 followed by 2 weeks of no treatment. Phase 1 basket trial focuses initially on prostate cancer during dose escalation and expands to ovarian, breast, head and neck, lung, pancreatic, and bladder cancers in Phase 1b.
• GTB-7550 CD19-targeted TriKE® candidate for lymphoid malignancies and autoimmune disease. The third TriKE® candidate to enter human clinical testing as of May 2026.

Quantifiable outcome

• Three TriKE candidates advanced into human clinical trials by May 2026
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

One partnership is on record.

• University of MinnesotacoreStrategic or Co-development PartnerGT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. The license covers the NK cell engager platform originally developed at the university. The university is entitled to receive royalties should commercial sales of product using the TriKE technology be realized. GT Biopharma also sponsors Phase 1 clinical trials through agreements with the University of Minnesota, with an agreement providing up to approximately $3.8 million over three years to support GTB-5550 research. Dr. Jeffrey Miller (Deputy Director, Masonic Cancer Center, University of Minnesota) serves as Consulting Senior Medical Director of GT Biopharma and presented at the 10th Anniversary Innate Killer Summit on behalf of the company. Dr. Nicholas Zorko (Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota) is leading the GTB-5550 clinical trial.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nkarta Therapeutics: Nkarta is a clinical-stage NK cell therapy company developing allogeneic and gene-engineered NK cell products for hematologic malignancies and solid tumors — a directly comparable NK-focused peer with public-market exposure and similar clinical-stage profile.
• Fate Therapeutics: Fate Therapeutics develops off-the-shelf iPSC-derived NK cell and T-cell immunotherapies for cancer. It competes in the same NK cell therapy category as GT Biopharma with broader pipeline scope and significantly greater capital resources.
• Innate Pharma: Innate Pharma is a clinical-stage biopharmaceutical company developing NK cell-based immunotherapies, including NK cell engagers and ADCs — a directly comparable NK-focused peer with established clinical programs in both hematologic and solid tumor indications.
• Century Therapeutics: Century Therapeutics develops iPSC-derived NK and T cell therapies for cancer, making it a directly comparable NK-focused peer operating in the same immuno-oncology cell therapy category as GT Biopharma.
• Dragonfly Therapeutics: Dragonfly develops TriNKETs (NK cell engager therapies) that bridge NK cells to tumor targets using a similar multi-specific protein architecture to TriKE, positioning it as a direct peer in the NK cell engager space.
• NkGen Biotech: NkGen Biotech develops autologous and allogeneic NK cell therapies for solid tumors, including neurodegenerative indications. It is a directly comparable NK-focused peer with clinical-stage assets overlapping TriKE's solid tumor focus.
• Affimed NV: Affimed develops innate immune cell engagers (e.g., AFM13, AFM28) that recruit NK cells to tumors — the closest direct competitor to GT Biopharma's TriKE platform, with overlapping mechanism (CD16A engagement) and clinical-stage NK engager assets in both hematologic and solid tumor indications.

Emerging players

• Compass Therapeutics: Compass Therapeutics is a clinical-stage immuno-oncology company developing bispecific antibodies and NK cell engagers (e.g., CTX-471), making it a relevant emerging peer in the immuno-oncology engager and NK cell engagement space.
• Cytovia Therapeutics: Cytovia is a clinical-stage immuno-oncology company developing NK cell therapeutics and engager molecules, including iPSC-derived NK cells and multifunctional NK engagers — positioning it as a relevant emerging peer in the NK cell therapy category.
• ImmunityBio: ImmunityBio develops NK cell therapies and IL-15-based immunotherapies (Anktiva) for cancer. Its use of IL-15 as an NK cell activator directly overlaps with the TriKE mechanism, making it a thematically relevant emerging peer in the broader NK/IL-15 space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/oxisintl
• Facebookfacebook.com/oxisinternationalinc
• LinkedInlinkedin.com/company/oxis-international-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds11 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GT Biopharma